PD-1或PD-L1抑制剂疗效与PD-L1表达状态的荟萃分析
该荟萃分析纳入8项随机对照试验共4174例晚期或转移性癌症患者,评估PD-1或PD-L1抑制剂对比传统药物的疗效。结果显示,无论PD-L1阳性(HR 0.66,95%CI 0.59-0.74)还是阴性(HR 0.80,95%CI 0.71-0.90),抑制剂均显著延长总生存期,但阳性与阴性患者间疗效差异显著(交互P=0.02)。结论提示PD-L1表达状态单独不足以决定是否适用PD-1或PD-L1阻断治疗。
要点
- PD-1/PD-L1抑制剂在PD-L1阳性和阴性患者中均显著优于传统治疗。
- PD-L1阳性患者获益更显著(HR 0.66),阴性患者亦获益(HR 0.80)。
- PD-L1表达状态单独不足以筛选免疫治疗获益人群。
核心结论
- PD-1或PD-L1阻断治疗对PD-L1阳性和阴性患者均优于传统治疗,但PD-L1表达状态单独不足以决定治疗选择。
研究设计与样本
- 随机对照试验的荟萃分析,检索PubMed、Embase、Cochrane数据库及ASCO和ESMO会议摘要至2018年3月。
- 纳入8项随机对照试验,共4174例晚期或转移性癌症患者。
- PD-L1阳性或阴性阈值定义为免疫组化染色PD-L1阳性细胞占肿瘤细胞或肿瘤与免疫细胞1%。
主要发现
- PD-L1阳性患者(n=2254)接受PD-1或PD-L1抑制剂对比传统药物,总生存期显著延长(HR 0.66,95%CI 0.59-0.74)。
- PD-L1阴性患者(n=1920)接受PD-1或PD-L1抑制剂对比传统药物,总生存期亦显著延长(HR 0.80,95%CI 0.71-0.90)。
- PD-L1阳性与阴性患者间疗效差异显著(交互P=0.02)。
- 长期临床获益在干预药物、癌症组织学类型、随机分层方法、免疫组化评分系统、药物靶点、对照组类型和随访时间等方面一致。
关键数值与推荐
- PD-L1阳性阈值:免疫组化染色PD-L1阳性细胞占肿瘤细胞或肿瘤与免疫细胞1%。
- 纳入药物包括avelumab、atezolizumab、durvalumab、nivolumab和pembrolizumab。
临床怎么用
- PD-1或PD-L1抑制剂可考虑用于PD-L1阳性和阴性患者,但需综合其他因素决策。
- 不应仅凭PD-L1表达状态决定是否使用PD-1或PD-L1阻断治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the relative efficacy of programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors versus conventional drugs in patients with cancer that were PD-L1 positive and PD-L1 negative. DESIGN: Meta-analysis of randomised controlled trials. DATA SOURCES: PubMed, Embase, Cochrane database, and conference abstracts presented at the American Society of Clinical Oncology and European Society of Medical Oncology up to March 2018. REVIEW METHODS: Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that had available hazard ratios for death based on PD-L1 positivity or negativity were included. The threshold for PD-L1 positivity or negativity was that PD-L1 stained cell accounted for 1% of tumour cells, or tumour and immune cells, assayed by immunohistochemistry staining methods. RESULTS: 4174 patients with advanced or metastatic cancers from eight randomised controlled trials were included in this study. Compared with conventional agents, PD-1 or PD-L1 inhibitors were associated with significantly prolonged overall survival in both patients that were PD-L1 positive (n=2254, hazard ratio 0.66, 95% confidence interval 0.59 to 0.74) and PD-L1 negative (1920, 0.80, 0.71 to 0.90). However, the efficacies of PD-1 or PD-L1 blockade treatment in patients that were PD-L1 positive and PD-L1 negative were significantly different (P=0.02 for interaction). Additionally, in both patients that were PD-L1 positive and PD-L1 negative, the long term clinical benefits from PD-1 or PD-L1 blockade were observed consistently across interventional agent, cancer histotype, method of randomisation stratification, type of immunohistochemical scoring system, drug target, type of control group, and median follow-up time. CONCLUSIONS: PD-1 or PD-L1 blockade therapy is a preferable treatment option over conventional therapy for both patients that are PD-L1 positive and PD-L1 negative. This finding suggests that PD-L1 expression status alone is insufficient in determining which patients should be offered PD-1 or PD-L1 blockade therapy.
引用
- Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018. PMID: 30201790. doi:10.1136/bmj.k3529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。